Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool.

Autor: Schmieder V; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Fieder J; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Drerup R; Early Stage Bioprocess Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Gutierrez EA; Early Stage Bioprocess Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Guelch C; Late Stage Upstream Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Stolzenberger J; Late Stage Downstream Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Stumbaum M; Early Stage Pharmaceutical Development, Pharmaceutical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Mueller VS; Early Stage Analytics, Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Higel F; Early Stage Analytics, Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Bergbauer M; Late Stage Analytics, Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Bornhoefft K; Characterization Technologies, Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Wittner M; Global CMC Experts NBE, Global Quality Development, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Gronemeyer P; Cell Banking & Inoculum, Focused Factory CS&T, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Braig C; CST Transfer, Focused Factory CS&T, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Huber M; Process Transfer Cell Culture, Focused Factory Drug Substance, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Reisenauer-Schaupp A; R&D PM NBE, Global R&D Project Management and Development Strategies, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Mueller MM; CMC PM Process Industrialization Germany, Global Biopharma CMC Project Mgmt&TechRA, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Schuette M; Global Technology Management, Global Innovation & Alliance Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Puengel S; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Lindner B; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Schmidt M; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Schulz P; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Fischer S; Cell Line Development, Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. Electronic address: simon.fischer@boerhinger-ingelheim.com.

Publikováno v: Journal of biotechnology [J Biotechnol] 2022 Apr 10; Vol. 349, pp. 53-64. Date of Electronic Publication: 2022 Mar 24.

Visualisation of intracellular production bottlenecks in suspension-adapted CHO cells producing complex biopharmaceuticals using fluorescence microscopy.

Autor: Mathias S; University of Applied Sciences Biberach, Institute of Applied Biotechnology, Hubertus-Liebrecht-Straße 35, 88400 Biberach, Germany. Electronic address: mathias@hochschule-bc.de., Fischer S; Boehringer Ingelheim Pharma GmbH & Co KG, Cell Culture Development CMB, Birkendorfer Straße 65, 88397 Biberach, Germany., Handrick R; University of Applied Sciences Biberach, Institute of Applied Biotechnology, Hubertus-Liebrecht-Straße 35, 88400 Biberach, Germany., Fieder J; Boehringer Ingelheim Pharma GmbH & Co KG, Early Stage Bioprocess Development, Birkendorfer Straße 65, 88397 Biberach, Germany., Schulz P; Boehringer Ingelheim Pharma GmbH & Co KG, Cell Culture Development CMB, Birkendorfer Straße 65, 88397 Biberach, Germany., Bradl H; Boehringer Ingelheim Pharma GmbH & Co KG, Cell Culture Development CMB, Birkendorfer Straße 65, 88397 Biberach, Germany., Gorr I; Boehringer Ingelheim Pharma GmbH & Co KG, Early Stage Bioprocess Development, Birkendorfer Straße 65, 88397 Biberach, Germany., Gamer M; Boehringer Ingelheim Pharma GmbH & Co KG, Early Stage Bioprocess Development, Birkendorfer Straße 65, 88397 Biberach, Germany., Otte K; University of Applied Sciences Biberach, Institute of Applied Biotechnology, Hubertus-Liebrecht-Straße 35, 88400 Biberach, Germany.

Publikováno v: Journal of biotechnology [J Biotechnol] 2018 Apr 10; Vol. 271, pp. 47-55. Date of Electronic Publication: 2018 Mar 02.

A single-step FACS sorting strategy in conjunction with fluorescent vital dye imaging efficiently assures clonality of biopharmaceutical production cell lines.

Autor: Fieder J; Early Stage Bioprocess Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Schulz P; Cell Culture Development CMB, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Gorr I; Early Stage Bioprocess Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Bradl H; Cell Culture Development CMB, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany., Wenger T; Global NBE/Biosimilar CMC experts, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.

Publikováno v: Biotechnology journal [Biotechnol J] 2017 Jun; Vol. 12 (6). Date of Electronic Publication: 2017 May 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Repressing expression of difficult-to-express recombinant proteins during the selection process increases productivity of CHO stable pools.

Autor: Maltais JS; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada., Lord-Dufour S; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada., Morasse A; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada., Stuible M; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada., Loignon M; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada., Durocher Y; Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, Québec, Canada.; Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.

Publikováno v: Biotechnology and bioengineering [Biotechnol Bioeng] 2023 Oct; Vol. 120 (10), pp. 2840-2852. Date of Electronic Publication: 2023 May 26.